Restasis costs roughly $600 or more for a 30-day supply without insurance, making it one of the pricier prescription eye drops on the market. The high price comes down to a combination of aggressive patent protection that kept generics off the market for nearly two decades, a formulation that’s genuinely difficult to replicate, and limited competition even now that generics exist.
Patent Strategies That Blocked Generics for Years
Restasis was first approved by the FDA in 2002, and its manufacturer, Allergan (now owned by AbbVie), used a series of legal strategies to protect its market exclusivity far beyond the original patent life. The most notorious move came in 2017, when Allergan transferred its Restasis patents to the Saint Regis Mohawk Tribe of New York. The idea was to invoke the tribe’s sovereign immunity to shield the patents from a federal review process designed to cancel invalid patents. Allergan agreed to pay the tribe $13.75 million upfront and up to $15 million per year in exchange.
The strategy drew widespread condemnation. A federal judge called it an attempt to “enjoy the considerable benefits of the U.S. patent system without accepting the limits that Congress has placed on those benefits.” The judge ruled that sovereign immunity shouldn’t be treated as a “monetizable commodity,” and Allergan ultimately lost its patent protections in court. But the years of litigation accomplished something valuable for the company: delay. Every month a generic competitor stayed off the market was another month of full-price sales for a drug that generated billions in revenue.
The first generic version of Restasis, made by Mylan Pharmaceuticals, wasn’t approved by the FDA until February 2022, a full 20 years after the brand-name product launched. That two-decade window of exclusivity allowed Allergan to set and raise prices without competitive pressure.
The Formulation Is Harder to Copy Than Most Drugs
Restasis isn’t a simple solution you dissolve in water. It’s an oil-in-water nanoemulsion, a complex formulation where tiny droplets of oil carry the active ingredient (cyclosporine) suspended in a water-based liquid. This design helps the drug stay on the eye’s surface longer and penetrate more effectively, but it also makes manufacturing tricky.
Small changes in temperature, mixing time, or the process used to shrink oil droplets can alter the emulsion’s properties in ways that affect how the drug is released and absorbed. Research has shown that formulations with identical ingredients and similar physical measurements (droplet size, viscosity, pH) can still behave differently depending on how they were manufactured. This sensitivity makes consistent production expensive and quality control demanding.
For generic manufacturers, the challenge is even steeper. The FDA requires generic eye drops to prove they’re pharmaceutically and biologically equivalent to the brand-name product. Unlike oral drugs, where you can measure blood levels to confirm equivalence, topical eye products don’t enter the bloodstream in meaningful amounts. Proving equivalence for a complex ophthalmic emulsion has been described by researchers as genuinely difficult, which is part of why it took so long for generics to reach the market even after legal barriers started falling.
Limited Competition Keeps Prices High
Even with generics now available, the competitive landscape for cyclosporine eye drops remains thin. The manufacturing complexity means relatively few companies have attempted to make a generic version, and the ones that exist haven’t driven prices down as dramatically as generics do for simpler drugs like tablets or capsules. A generic cyclosporine emulsion costs less than brand-name Restasis, but the savings gap is narrower than what you’d see with, say, a generic blood pressure pill.
The only major brand-name competitor, Xiidra, doesn’t put much downward pressure on Restasis pricing either. Xiidra actually costs more, running about $730 for a 30-day supply without insurance compared to Restasis at roughly $640. When your closest competitor is priced even higher, there’s little incentive to lower your own price.
What Insurance Typically Covers
On Medicare Part D plans, Restasis generally falls on Tier 3, which is the preferred brand-name tier. This means you’ll pay a moderate copay rather than the full retail price, but it’s still more than you’d pay for a Tier 1 or Tier 2 generic. Some plans may steer you toward the generic cyclosporine emulsion first, which would sit on a lower tier with a smaller copay.
If you have commercial insurance, your out-of-pocket cost depends heavily on your plan’s formulary and whether Restasis or its generic is listed. Some plans require prior authorization, meaning your doctor needs to document that you’ve tried cheaper alternatives first.
Ways to Reduce Your Cost
The most straightforward option is asking your doctor or pharmacist about generic cyclosporine ophthalmic emulsion. It contains the same active ingredient at the same concentration and is considered equally safe and effective. Prices vary by pharmacy and region, so it’s worth calling a few pharmacies to compare cash prices.
AbbVie runs a patient assistance program called myAbbVie Assist for people who are uninsured, underinsured, or can’t afford their medication. Eligibility is evaluated on a case-by-case basis, and even patients with Medicare Part D may qualify. The company doesn’t publish specific income cutoffs, so you’d need to apply and see if you’re approved.
Pharmacy discount cards and coupon programs (like GoodRx) can sometimes reduce the cash price significantly, particularly for the generic version. These discounts vary by location and change frequently, so checking at the point of purchase gives you the most accurate number.